Your email has been successfully added to our mailing list.

×
-0.025 -0.025 -0.00758333333333342 0.00833333333333334 0.0174999999999999 0.0256666666666666 0.0170833333333333 0.00833333333333334
Stock impact report

Seelos Therapeutics to get US patent for SLS-007 linked to treating neurodegenerative diseases [Seeking Alpha]

Seelos Therapeutics, Inc. (SEEL) 
Last seelos therapeutics, inc. earnings: 5/21 05:12 pm Check Earnings Report
Company Research Source: Seeking Alpha
Seelos Therapeutics to get US patent for SLS-007 linked to treating neurodegenerative diseasesMay 18, 2022 8:52 AM ETSeelos Therapeutics, Inc. ()By:RavikashSA News Editormaybefalse/E+ via Getty ImagesThe company the the notice of allowance covers the method of treating several neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease (PD), Lewy body dementia and multiple system atrophy, through contacting alpha-synuclein (a-synuclein) protofilaments with an effective amount of SLS-007. Show less Read more
Impact Snapshot
Event Time:
SEEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
SEEL alerts

from News Quantified
Opt-in for
SEEL alerts

from News Quantified